Mr. Moran has served as Chief Executive Officer since October 1, 2018. Prior to joining the Company, from 2015 to September 2018, Mr. Moran served as President of the Americas, ConvaTec Group Plc (LON: CTEC) (“ConvaTec”), an international medical products and technologies company, offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. Prior to his employment at ConvaTec, Mr. Moran held roles in sales, marketing and general management over the course of eighteen years at Coviden plc (“Coviden”), an Irish-headquartered global health care products company and manufacturer of medical devices and supplies. While at Coviden, until 2015, Mr. Moran served simultaneously as VP and General Manager of both the SharpSafety and Monitoring & Operating Room divisions. Following the 2015 acquisition of Covidien by Medtronic (NYSE:MDT), Mr. Moran was named the Global Vice President and General Manager of the Patient Care and Safety Division. Mr. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Mr. Moran earned a B.A. in Organizational Communication at The State University of New York at Geneseo. Mr. Moran was selected as a director because of his broad commercial experience and leadership in the medical technology sector.
With 30 years of experience in the medical device industry, Mr. Pomeranz brings a strong track record of success in both start-ups and in large multinational organizations.
Prior to joining Motus GI in 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems. Other previous positions include serving as a Vice President at Cordis, a Johnson & Johnson company, and in senior leadership roles at Cardiac Pathways Corporations and Cardiovascular Imaging Systems, both acquired by Boston Scientific Corporation.
Mr. Pomeranz earned a MSc in Biomedical Engineering from the University of Miami, a BS in Mechanical Engineering from Union College and currently holds over 40 patents.
Mr. Taylor has over 20 years of experience serving as a financial officer, operating executive and business advisor across start-ups, emerging growth and Fortune 500 companies in both the U.S. and abroad.
Prior to joining Motus GI in August 2017, Mr. Taylor was the President and Chief Financial Officer of Angel Medical Systems, Inc., a medical device company that develops and manufactures continuous intra-cardiac ischemia monitoring and alerting systems. While at Angel Medical Systems, Mr. Taylor supervised the operations of more than fifty (50) employees in the United States and Brazil, while also overseeing the financial planning and analysis activities, capital raising efforts, and implementation of capital and operating budgets. Prior to his time at Angel Medical Systems, Mr. Taylor served as a Practice Leader for AC Lordi Consulting, a professional services firm, providing finance, accounting and strategy services. Before joining AC Lordi, Mr. Taylor was the Chief Financial Officer and Corporate Director of Operations for Safe3w, Inc., a security software company, which was acquired by iPass (NASDAQ: IPAS) in 2004.
Mr. Taylor earned a high-honors MBA with a concentration in Accounting and Finance from Northeastern University and a BA in Political Science and Economics from McGill University.
Mr. Hutchison has over 25 years of executive sales leadership and new market development experience in the medical device industry.
He most recently served as Vice President of U.S. Sales for Bio2 Medical where he was responsible for leading all commercial activities from FDA 510k clearance through national launch for market development technology for the prevention of pulmonary embolism. Prior to that, he served as Area Vice President of Sales for Medtronic GI Solutions (NYSE: MDT) where he led the Western Division of Medtronic's GI business, managed the integration of two major acquisitions and led the growth of the organization from 33 territories and 4 regions to 135 territories and 18 regions. Previously, he served as Director of U.S. Sales for BÂRRX Medical, where he led the U.S. sales organization and drove commercialization of BÂRRX's endoscopic treatment devices for Barrett's Esophagus. Mr. Hutchison was an integral part of the BÂRRX acquisition team when it was purchased in 2011 by Coviden and later acquired by Medtronic. During that time, he oversaw the hiring of 50 professionals and grew the company's domestic business by 20% over prior year, with 40% reduction in CMS reimbursement. Prior to BÂRRX, Mr. Hutchison spent 17 years at Boston Scientific (NYSE: BSX) in a variety of sales, sales management and market development roles in the endoscopy and cardiology divisions.
Mr. Hutchison holds a BS in Marketing from Bradley University and a MBA from the University of Phoenix.
Mr. Balog has extensive knowledge in product management, project management, product roadmap development, engineering, operations and production.
Prior to joining Motus GI in June 2017, Mr. Balog served as the Director of Operations and Engineering at EndoChoice. Earlier, he served as Director of Product Management at Given Imaging, Vice President of Product and Test Engineering at OptimalPlus and Product Test Engineer at Intel Fab 18. He has been granted 14 patents in the United States and has presented at various international conferences.
Mr. Balog earned his BSc in Electrical & Computer Engineering at Ben-Gurion University of the Negev.